What is TB-500? The thymosin beta-4 fragment explained

This profile covers TB-500 from the laboratory side: what the molecule is, what the parent protein literature reports, what the fragment-specific studies actually measured and where the evidence stops. It sits in the research topics index under compound profiles, which separate what a study measured from what it is often taken to mean.

It covers published research only and does not describe any use of TB-500 in people or animals.

What TB-500 is, chemically

TB-500 is written as Ac-LKKTETQ: leucine, lysine, lysine, threonine, glutamic acid, threonine and glutamine, with an acetyl group on the N-terminus. Rahaman and colleagues (2024, Journal of Chromatography B) describe it as derived from the active site of thymosin beta-4, and note that the biological functions reported for that region, including actin binding, were described for the unacetylated sequence LKKTETQ. Calculated from the sequence, the acetylated peptide has the formula C38H68N10O14 and a molecular weight of about 889 g/mol.

Terms such as acetylation, metabolite and orbitrap are defined in plain language across the article library.

What the parent protein literature reports

Much of what is written about TB-500 is borrowed from research on full-length thymosin beta-4. A review by Goldstein, Hannappel, Sosne and Kleinman (2012, Expert Opinion on Biological Therapy) describes thymosin beta-4 as a low molecular weight, naturally occurring peptide that is released by platelets, macrophages and other cell types after injury. The authors report that it binds actin and promotes cell migration, and that it reduces the number of myofibroblasts in wounds.

That review covers the protein’s basic biology and its study in skin, eye, heart and brain models. It is a review of the 43-residue protein. It does not set out to show that a seven-residue acetylated fragment does the same things.

What fragment-specific studies measured

Analytical and metabolite work

The Rahaman study set out to measure TB-500 and its breakdown products at the same time. The team developed and validated a UHPLC-Q-Exactive orbitrap mass spectrometry method, then studied how TB-500 is broken down in human serum, in several in vitro enzyme systems and in urine from rats given the peptide.

• Ac-LK was the main metabolite. It reached the highest concentration in rat urine in the first six hours.
• Ac-LKK lasted longest. The authors detected it up to 72 hours after administration.
• Only one fragment was active in their assay. In fibroblast wound-closure experiments, Ac-LKKTE showed significant activity compared with control. The parent peptide and the other metabolites did not, and none of the compounds showed cytotoxicity.

The authors suggest that wound-healing activity previously attributed to TB-500 may come from the metabolite Ac-LKKTE rather than from the parent form. That is a hypothesis drawn from cell culture, and it shows why separating a parent peptide from its fragments matters. The same problem for identity testing is covered in orthogonal identification.

A rat tendon model

An exploratory study by Biçer and colleagues (2026, Joint Diseases and Related Surgery) used 32 male Sprague-Dawley rats that underwent standardised Achilles tendon transection and repair. The animals were split into four groups of eight: control, BPC-157, TB-500 and the two combined. At four weeks the tendons were tested for load to failure or examined histologically.

• Biomechanics. Maximum load to failure was higher than control in the TB-500 group, with statistical significance.
• Histology. Total Bonar scores were lower in the TB-500 group and total Movin scores were lower in the TB-500 and combined groups, which the authors read as better tendon architecture.
• Collagen. Type I collagen expression did not differ significantly between groups. Type III collagen expression did.
• No added effect. The combination did not outperform either compound alone.

The authors call the work exploratory and say longer studies are needed. Individual papers like this one are broken down in the study summaries.

What TB-500 research does not establish

A scoping review by Tewari and colleagues (2026, American Journal of Sports Medicine) looked at six peptides, TB-500 among them, in musculoskeletal research. It found that 67% of the identified publications used preclinical animal models, most often rats, and that human studies were limited to a handful of investigations, most without robust controls.

• Protein findings are not fragment findings. Much of the mechanistic picture comes from full-length thymosin beta-4.
• The active species is unresolved. Metabolite work raises the possibility that a fragment, not TB-500 itself, accounts for some reported activity.
• Animal results are early and small. The tendon study used eight rats per group and one four-week time point.
• Human evidence is thin. The scoping review concluded that claimed benefits remain unsubstantiated by current human trials.

How we decide what a study can and cannot support is set out in how we write.

Checking a TB-500 certificate of analysis

Because TB-500 breaks down into shorter acetylated fragments, a certificate should show that the material in the vial is the full seven-residue sequence and not a mixture of pieces. These are the points to look for.

• Sequence stated as Ac-LKKTETQ, with the N-terminal acetyl group named
• Molecular formula and weight consistent with the acetylated sequence, about 889 g/mol
• Identity confirmed by mass spectrometry, not by HPLC retention time alone
• Chromatogram showing individual impurity peaks, not only a single purity figure
• Truncated or deleted sequences reported where present
• Peptide content or water content stated alongside purity
• Lot number on the certificate identical to the lot on the vial label

The identity line matters most. A purity percentage on its own cannot tell a full-length peptide from a shorter fragment with similar chromatography, which orthogonal identification explains in detail.

Frequently asked questions